Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes.

Egeberg, Alexander; Merola, Joseph F; Schäkel, Knut; Puig, Luis; Mahar, Patrick D; Wang, Isabella Yali; Pavo, Imre; Schuster, Christopher; Griffiths, Christopher E M

Egeberg, Alexander; Merola, Joseph F; Schäkel, Knut; Puig, Luis; Mahar, Patrick D; Wang, Isabella Yali; Pavo, Imre; Schuster, Christopher; Griffiths, Christopher E M.

Afiliação

Egeberg A; Bispebjerg and Frederiksberg Hospital, Copenhagen University, Copenhagen, Denmark.
Merola JF; Division of Rheumatology, Department of Dermatology and Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States.
Schäkel K; Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
Puig L; Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Mahar PD; Eli Lilly and Company, Indianapolis, IN, United States.
Wang IY; Department of Dermatology, Royal Children's Hospital, Faculty of Medicine, Nursing and Health Sciences, Skin Health Institute, The University of Melbourne, Melbourne, VIC, Australia.
Pavo I; Eli Lilly and Company, Indianapolis, IN, United States.
Schuster C; Eli Lilly and Company, Indianapolis, IN, United States.
Griffiths CEM; Eli Lilly and Company, Indianapolis, IN, United States.

Front Med (Lausanne) ; 9: 1092688, 2022.

Article em En | MEDLINE | ID: mdl-36777159

Palavras-chave

ixekizumab; moderate-to-severe psoriasis; obesity; prediabetes; type 2 diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google